Últimas noticias sobre Atossa Therapeutics (NASDAQ:ATOS) Bolsa

Atossa Therapeutics

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics Inc

ATOS ORIGIN SA ORD by Atos Origin SA

Atos SE

ATOS ORIGIN SA UNSP/ADR by Atos Origin SA

&nbsp;Palo Alto Networks&#xAE; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>), the global cybersecurity leader, today announced its latest advancements in <a href="https://www.paloaltonetworks.com/sase">Prisma</a>&#xAE; <a href="https://www.paloaltonetworks.com/sase">SASE</a>, the industry's most comprehensive secure access service edge (SASE) solution, including the unveiling of <a href="https://www.paloaltonetworks.com/sase/prisma-access-browser">Prisma Access Browser</a> 2.0, the world's only SASE-native secure browser. Prisma Access Browser 2.0, along with Endpoint Data Loss Prevention (DLP) and expanded cloud presence with Oracle Cloud Infrastructure (OCI), are new Prisma SASE capabilities designed to secure generative AI (GenAI) usage, improve user experience and enhance operational resilience in the modern workplace.
<a href="https://www.paloaltonetworks.com/resources/infographics/the-state-of-security-in-the-modern-organization">Eighty-five percent</a> of work today is happening in browsers, leading to potential data exposure and monitoring gaps. Palo Alto Networks <a href="https://www.paloaltonetworks.com/resources/research/unit-42-incident-response-report">2025 Unit 42 Incident Report</a> found that almost half (44%) of security incidents involved malicious activities initiated or enabled through employees' browsers, such as phishing, URL redirect abuse and malware downloads.
"A secure browser extends SASE protection to where knowledge workers spend most of their time, securing third-party access, supporting BYOD, and reducing an organization's reliance on legacy infrastructure like VDI," said John Grady, principal analyst at Enterprise Strategy Group, now part of Omdia. "Palo Alto Networks unique approach of integrating its Prisma Access Browser with Prisma SASE helps organizations extend the same protection from advanced threats, user experience monitoring, and GenAI app protection from the network into the browser, ensuring users are protected, efficient, and productive."

News

PANW

Palo Alto Networks Unveils Prisma Access Browser 2.0, World's Only SASE-Native Secure Browser

On Friday, April 25, U.S. markets closed higher, capping a strong week fueled by easing U.S.-China trade tensions and solid earnings. The S&amp;P 500 and Nasdaq gained, led by AI-related megacaps, while the Dow lagged.
Most S&amp;P 500 firms beat earnings expectations, though forward guidance reflected economic uncertainty. Consumer sentiment stayed weak while Alphabet rallied and Intel slumped.
In economic data, the University of Michigan&#8217;s consumer sentiment index for April was revised up to 52.2, improving from the initial estimate of 50.8 but still down from March&#8217;s 57.
Among the S&amp;P 500&#8217;s 11 major sectors, consumer discretionary and tech led the gains, while materials recorded the biggest percentage decline.
The Dow Jones Industrial Average was up 0.05% to 40,113.50, the S&amp;P 500 rose 0.74% to 5,525.21, and the Nasdaq jumped 1.26% to 17,382.94.
Asia Markets Today
<ul>
<li>On Monday, Japan&#8217;s Nikkei 225 gained 0.35% and closed at 35,831.00, led by gains in the Real Estate, Banking, and Textile sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 gained 0.36%, ending the session at 7,997.10, led by gains in the Energy, IT, and Consumer Discretionary sectors.</li>
<li>India&#8217;s Nifty 50 was up 1.17% at 24,320.35, and Nifty 500 rose 1.13% to 22,094.45.</li>
<li>China&#8217;s Shanghai Composite slid 0.20% to 3,288.41, and Shanghai Shenzhen CSI 300 was down 0.14% at 3,781.62.</li>
<li>Hong Kong&#8217;s Hang Seng closed 0.04% lower at 21,971.96.</li>
</ul>
Eurozone at 05:45 AM ET
<ul>
<li>The European STOXX 50 was up 0.79%.</li>
<li>Germany&#8217;s DAX gained 0.83%.</li>
<li>France&#8217;s CAC 40 rose 0.89%.</li>
<li>U.K.&#8217;s FTSE 100 index traded higher by 0.39%.</li>
</ul>
Commodities at 05:45 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 0.21% at $62.90/bbl, and Brent was down 0.20% at $65.67/bbl.</li>
<li>Natural Gas rose 1.35% to $3.156.</li>
<li>Gold was trading lower by 0.28% at $3,289.40, Silver was down 0.50% to $32.845, and Copper slid 0.53% to $4.8692.</li>
<li>Gold prices fell as easing U.S.-China trade tensions reduced safe-haven demand. Investors await key U.S. data, while Copper edged lower despite hopes for China&#8217;s economic stimulus boost.</li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were up 0.01%, S&amp;P 500 futures fell 0.10%, and Nasdaq 100 futures declined 0.09%.
Forex at 05:45 AM ET
<ul>
<li>The U.S. Dollar Index rose 0.13% to 99.60, USD/JPY was down 0.15% to 143.46, and USD/AUD gained 0.01% to 1.5628.</li>
<li>Global markets stayed near three-week highs as easing tariff concerns lifted sentiment, though confusion over U.S. trade policy persisted. Stocks rose modestly, the dollar struggled, and investors focused on key U.S. earnings, jobs data, and upcoming elections.</li>
</ul>
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Advances, Gold Retreats On Hopes Of Fading Uncertainty - Global Markets Today While US Slept

The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click <a href="https://viavid.webcasts.com/starthere.jsp?ei=1718118&amp;tp_key=02fe2f82c4">here</a> to register
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
This data was presented at the <a href="https://www.elite-pedgi.com/">Annual ELITE PED-GI Congress</a> by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study

Biotech

Events

General

JAGX

Jaguar Health To Present Initial Results From Proof-of-Concept Study of Crofelemer For Rare Diseases Microvillus Inclusion Disease And Short Bowel Syndrome With Intestinal Failure

Earnings

Earnings Misses

BSRR

Sierra Q1 EPS $0.65 Misses $0.66 Estimate, Sales $36.75M Miss $37.51M Estimate

ZJK Industrial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) reported quarterly earnings of $0.06 per share. This is a 53.85 percent decrease over earnings of $0.13 per share from the same period last year. The company reported $37.81 million in sales this quarter. This is a 30.15 percent increase over sales of $29.05 million the same period last year.

ZJK Industrial FY EPS $0.06 Down From $0.13 YoY, Sales $37.81M Up From $29.05M YoY

Newegg Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) reported $1.24 million in sales this quarter. This is a 99.92 percent decrease over sales of $1.50 billion the same period last year.

NEGG

Newegg Commerce FY24 Sales $1.24M Down From $1.50B YoY

Macro Economic Events

Global

Economics

Bessent Says India Could Be One Of First Trade Deals We Sign

<ul>
<li>Findings in a younger, commercially insured population build on Medicare-based CAMELOT results, expanding the generalizability of Zio LTCM's clinical impact across patient groups.</li>
<li>Latest data showed Zio LTCM was associated with higher diagnostic yield and lower likelihood of repeat testing and cardiovascular events compared to all other LTCM products.</li>
</ul>
SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Ikwp3f39jnu34tuHM0kHVjLa90aVBTaCBY2hja6eWJExuBXp8_Y6rAsaxWHfbSueKtdCrmddSVqac7FC2MVt8bz0OAy0xibL25f77FW-JPA=">iRhythm Technologies, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) announced results from a large real-world retrospective analysis presented at the Heart Rhythm Society's annual meeting, HRS2025, held April 24–27 in San Diego, CA, The Assessment of Variation in AmbuLatory Cardiac MONitoring: Real-World Evidence of Commercially Insured Beneficiaries (AVALON) study—drawing on claims data from a cohort of 428,707 commercially insured patients—represents the largest real-world comparative evaluation of ambulatory cardiac monitoring (ACM) among this population to date, and reinforces the clinical superiority of the Zio&#xAE; long-term continuous monitoring (LTCM) service.

IRTC

iRhythm Presents AVALON Study Results at HRS2025, Showcasing Largest Real-World ACM Analysis

TDH Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETZ#NASDAQ">PETZ</a>) reported quarterly earnings of $0.26 per share. This is a 111.35 percent increase over losses of $(2.29) per share from the same period last year. The company reported $563.73 thousand in sales this quarter. This is a 74.66K percent increase over sales of $754.00 the same period last year.

PETZ

TDH Hldgs FY EPS $0.26 Up From $(2.29) YoY, Sales $563.73K Up From $754.00 YoY

&nbsp;80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidatesThe data underscores the precision of
&nbsp;
<ul>
<li>80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidates</li>
<li>The data underscores the precision of Evaxion's AI-Immunology&#x2122; platform in selecting therapeutically relevant vaccine targets</li>
<li>New findings show EVX-01 inducing a robust and durable immune response, further enhanced by booster immunizations
<ul>
<li>The ongoing phase 2 trial with EVX-01 remains on track for two-year data readout in the second half of 2025</li>
</ul>
</li>
</ul>

EVAX

Evaxion Biotech Announces Data Underscoring Ability Of Cancer Vaccine EVX-01

Market-Moving Exclusives

Exclusives

ARTL

EXCLUSIVE: Artelo Biosciences Tells Benzinga 'ART26.12 Phase 1 in healthy volunteers completes enrollment with clinical data announcement expected this quarter'

EXCLUSIVE: Artelo Biosciences Tells Benzinga Co. Announces Publication Of New Peer-Reviewing Research Demonstrating ART26.12's Effectiveness In Treating Psoriasis

U.S. Treasury Secretary Bessent Says All Aspects Of Government Are In Contact With China; Up To China To De-escalate On Tariffs

Artelo Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) on Monday announced new research published in the peer-reviewed&nbsp;Journal of Investigative Dermatology describing the positive effects of ART26.12 in both in vitro <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">and </a><a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">in vivo</a><a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener"> psoriasis models</a>.
The research shows results comparable to immunomodulatory drugs with known serious adverse events.
The research highlights ART26.12, Artelo&#8217;s orally active, small-molecule inhibitor of Fatty Acid Binding Protein 5 (FABP5), and its potential ability to treat psoriasis.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42854815/why-is-hoth-therapeutics-stock-trading-over-100-higher-on-tuesday" rel="noreferrer noopener">Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?</a>
George Warren, PhD, Lead Author and Principal Scientist at Artelo, said, &#8220;We are excited to share the results on this novel target in psoriasis. Our findings demonstrate that ART26.12 has effects comparable to powerful immunomodulators, while its unique pharmacology leads to a significantly distinct expression of proteins and lipids in the skin.&#8221;
Dr. Warren added, &#8220;Pre-clinical IND-enabling studies with ART26.12, supported by a literature review of greater than 300 studies examining FABP inhibition, imply a low toxicological risk for ART26.12, which, if borne out in clinical studies, suggest FABP5 inhibition with an orally delivered small molecule may be an attractive, less costly, and safer approach for treating this debilitating chronic disease.&#8221;
A Phase 1 Single Ascending Dose study in healthy volunteers with ART26.12 has completed enrollment, and data announcements are expected in the second quarter of 2025.
The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN).
In addition to ART26.12 in CIPN, Artelo&#8217;s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders.
In January, Artelo Biosciences completed a safety review of the first cohort of eight healthy volunteers in the company&#8217;s <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42943914/exclusive-artelo-biosciences-concludes-first-cohort-of-healthy-volunteers-of-fabp-inhibitor-program" rel="noreferrer noopener">Phase 1 study of ART26.12</a>.&nbsp;
In December, Artelo Biosciences announced the presentation of preliminary data on ART27.13, a benzimidazole derivative being studied for&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42390296/artelo-biosciences-announces-presentation-of-phase-1-data-with-art27-13-in-cancer-related-anorexia" rel="noreferrer noopener">cancer-related anorexia</a>.
Artelo is evaluating ART27.13 in the Phase 1/2 trial in cancer-related anorexia, which is currently enrolling Phase 2 of the study.
In Phase 1, ART27.13 was orally administered at 150 to 650 microgram doses.
The investigational drug was well tolerated, with only mild to moderate adverse events observed in a minority of participants.
At one month of treatment, two-thirds of participants showed evidence that the drug was impacting their weight loss, with either stabilization or reversal of weight loss associated with their cancer.
Phase&nbsp;2 is accruing participants at a 650 microgram dosage with planned escalation at 4-week intervals up to a dose of 1300 micrograms per day. Initial data from the Phase 2 CAReS trial is anticipated by the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44074980/artelo-biosciences-provides-business-update-and-reports-fiscal-2024-year-end-financial-results" rel="noreferrer noopener">end of Q2 2025</a>.
Price Action: ARTL stock closed at $1.04 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45021274/merck-stays-confident-on-ma-despite-market-uncertainty-analyst" target="_blank" rel="noreferrer noopener">Merck Stays Confident On M&amp;A Despite Market Uncertainty: Analyst</a></li>
</ul>

Health Care

EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models

Silicom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILC#NASDAQ">SILC</a>) sees Q2 sales of $14.500 million-$15.500 million vs $14.94 million analyst estimate.

Guidance

SILC

Silicom Sees Q2 Sales $14.500M-$15.500M vs $14.94M Est

– Identified and prospectively replicated an EEG-based biomarker for placebo response in MDD –
– New data strengthen the mechanistic link between ALTO-300 and the EEG biomarker being used for patient selection; biomarker signature induced by activating 5-HT2C or depleting dopamine directly –
– Preclinical ALTO-101 rescue study underscores the therapeutic potential of this novel PDE4 inhibitor, and validates EEG theta response as a robust translational biomarker for CIAS –
Alto Neuroscience, Inc. ("Alto") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations at the Society of Biological Psychiatry (SOBP) Annual Meeting, in Toronto, Canada, held April 24-26, 2025.
"The biological and clinical insights we presented at SOBP support our precision psychiatry pipeline and mark important advancements for the field," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "To address the longstanding challenge of high placebo response in neuropsychiatric clinical development, we have successfully identified and prospectively replicated an EEG biomarker that captures placebo response patterns in patients with major depressive disorder. We believe this biomarker has the potential to reduce noise and improve the detection of true therapeutic effect."
Dr. Etkin continued, "We enhanced our understanding of the mechanistic link between ALTO-300 and the machine-learning derived, EEG biomarker used to identify patients who are more likely to respond to treatment. We showed that increasing 5-HT2C activity or directly depleting dopamine—both the opposite mechanistic effect of ALTO-300—resulted in greater EEG irregularity, consistent with a biomarker positive profile. Additionally, in a preclinical rescue study we demonstrated that ALTO-101 increased theta response, demonstrating its robustness as a translational biomarker for cognitive impairment associated with schizophrenia and potential pro-cognitive drug effect. We look forward to leveraging these findings to drive meaningful innovation in psychiatry and enhance clinical outcomes for patients."

ANRO

Alto Neuroscience Announces Multiple Presentations Made At The Society of Biological Psychiatry Annual Meeting, In Toronto, Canada, Held April 24-26, 2025

Palo Alto Networks Announces Intent To Acquire Protect AI, Terms Not Disclosed

Offerings

MSTR

MicroStrategy Sold 4.02M Shares For $1.40B From April 21-27; Acquired 15,355 BTC For $1.42B During April 21-27

Bessent Says Negotiations With Asian Trading Partners Going Very Well

Calidi Biotherapeutics Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NYSE">CLDI</a>) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the selection of IL15 superagonist (Il15-IL15Ra) as the first payload to be delivered into tumors using its systemic antitumor virotherapy platform, RTNova. New preclinical data were presented at the American Association for Cancer Research (AACR) Annual Meeting on April 27, 2025, in Chicago, IL.

CLDI

Calidi Biotherapeutics Says IL15 superagonist Chosen As First Payload To Be Delivered Into Tumors Using Systemic Antitumor Virotherapy Platform, RTNova

Press Releases

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Applauds U.S. Surgeon General's Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Legal

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

Management

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

ATOS

Alector

Anixa Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

C4 Therapeutics

Climb Bio

Coya Therapeutics

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Elutia

EXoZymes

Genelux

HilleVax

Immunic

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Seres Therapeutics

Macrogenics

OncoCyte

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

TScan Therapeutics

Vor Biopharma

Vaxart

XBiotech

Exagen

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Zura Bio Limited - Class A Ordinary shares

Zura Bio

Ascendiant Capital

HC Wainwright & Co.

Atossa Genetics

Screenshot 2024-04-01 at 9.57.34 PM

This Biotech Works On All Phases Of Breast Cancer, From Prevention To Post Surgery

Comments

Atossa Therapeutics

Noticias

Últimas noticias sobre Atossa Therapeutics (NASDAQ:ATOS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL